Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.84 |
| ▸ | MAOB | P27338 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 1/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.84 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7729482 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL29758518 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL537085 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL14541714 | 0.96 | ADORA2A (0.92) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL12628562 | 0.95 | ADORA2A (0.90) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL19074749 | 0.93 | ADORA2A (0.87) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7543907 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7543903 | 0.92 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL5967914 | 0.92 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| Istradefylline SCHEMBL633262 | 0.92 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555037-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG | 2017-01-31 | — | — | US | claimed |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2016-06-02 | — | — | US | claimed |
| US-20150164903-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2015-06-18 | — | — | US | claimed |
| US-7767686-B2 | Method of using adenosine receptor blockers during tissue ablation | COVIDIEN AG (CH) | 2010-08-03 | — | — | US | claimed |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | claimed |
| EP-2111231-A2 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NorthEastern University (US) | 2009-10-28 | — | — | EP | claimed |
| WO-2008147482-A2 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2008-12-04 | — | — | WO | claimed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| US-20070037833-A1 | Compositions and methods for inhibiting neurodegeneration | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2007-02-15 | — | — | US | claimed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| US-5859019-A | Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-01-12 | — | — | US | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| WO-2023215702-A2 | COMPOSITIONS FOR AND METHODS OF TREATMENT WITH MUTANT A1 ADENOSINE RECEPTOR PLASMID CDNAS | WILSON CONSTANCE (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230346883-A1 | COMPOSITIONS FOR AND METHODS OF TREATMENT WITH MUTANT A1 ADENOSINE RECEPTOR PLASMID cDNAs | ENDACEA, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-0628311-A1 | ANTIDEPRESSANT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| EP-0607607-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0565377-A1 | Therapeutic agents for use in the treatment of parkinson's disease | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| EP-0559893-A1 | XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | HIF1AN, HIF1A, EGLN3 | ADORA2A 6/4885ADORA3 38/4885ADORA2B 11/4885 |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA2B 2/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ADORA2A 414/4885ADORA3 473/4885ADORA2B 826/4885 |
| US-20150164903-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA2A 271/4885ADORA3 381/4885ADORA2B 339/4885 |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA2A 271/4885ADORA3 381/4885ADORA2B 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.